TOPICAL GENERIC DRUG EXCIPIENTS CAN BE DIFFERENT FROM REFERENCE
Executive Summary
TOPICAL GENERIC DRUG EXCIPIENTS CAN BE DIFFERENT FROM REFERENCE listed drug, a recent FDA Office of Generic Drugs memorandum on its interim inactive ingredients policy explains. "All excipients in a topical drug product are considered to be exception excipients" for which Title I of the Waxman-Hatch Act "allows changes from the reference listed drug," the memo states. The memo from OGD Acting Director Doug Sporn to Associate Director for Science and Medical Affairs Roger Williams summarizes OGD's interim inactive ingredient policy for filing and approving ANDAs for parenteral, ophthalmic, otic and topical generic drugs.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth